menu toggle

FormularyDecisions Connection Newsletter

Browse new features, discover platform releases, learn about upcoming events, and stay up to date on all the latest insights.

In this month's newsletter ..

 

June is myasthenia gravis awareness month


There are approximately 82,715 US adults living with myasthenia gravis in 2021.1 According to a claims-based analysis representing over 300 million patients in the US from 2011 to 2021, the overall incidence of myasthenia gravis in 2021 was 3.2 per 100,000 and the total prevalence was estimated to be 37.0 per 100,000 with similar estimates for males and females that increased with age.2

Leverage the information available on FormularyDecisions to familiarize yourself with myasthenia gravis.

Payer

 

The Clinical Guideline Snapshot on the 2020 American Academy of Neurology Consensus Guidance for the management of myasthenia gravis includes visual treatment algorithms and clearly lists out the significant changes since publication of the 2016 guideline for quick reference.

Reports from the Institute for Clinical and Economic Review (ICER) are uploaded to FormularyDecisions for easy access including one for myasthenia gravis.

The Metasearch Results on the myasthenia gravis disease page include a number of credible and reliable articles from third-party publications. Here are a sample of articles you can access through FormularyDecisions.


Manufacturers may also post relevant files within the Resource Center of a product page. For example, a research poster titled “Network meta-analysis of treatment options in generalized myasthenia gravis: impact on health-related quality of life outcome” presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting is posted on FormularyDecisions.

 

 

Available now:

MyInsights Program Survey Opportunities

Product surveys are an important way to share your insights with biopharma companies. Not only does your feedback communicate specific content requests to biopharma companies (eg, comparative effectiveness analysis, real-world evidence) so that they are more likely to post helpful files to FormularyDecisions, but it also helps biopharma companies identify potential evidence gaps that can be filled over time.

Log into FormularyDecisions to view all survey and feedback opportunities available. Earn points for completing surveys that can be redeemed in the form of gift cards and/or donated to a charity.

Below are links to the Product Page for surveys that are at the top of the list of all available surveys when you sort by “Most Recent” on FormularyDecisions.

Status
Product page with survey opportunities

Pre-approvala

CSL-312 (garadacimab)

IB-1001 (acetylleucine)

Linvoseltamab (REGN-5458)

mRNA-1345

Odronextamab (REGN-1979)

PD-0325901 (mirdametinib)

Vibrant capsule

YN-968D1 (rivoceranib)

FDA-approvedb

FILSUVEZ® (birch triterpenes topical gel)3


Don’t forget to also check out the following survey opportunities that may be leaving soon.

Status
Product page with survey opportunities

FDA-approvedb

ACTHAR® GEL (repository corticotropin injection)4

ASCENIV™ (immune globulin intravenous, human-slra)5

ELEVIDYS (delandistrogene moxeparvovec-rokl)6

ELFABRIO® (pegunigalsidase alfa-iwxj)7

ENHERTU® (fam-trastuzumab deruxtecan-nxki)8

LIBTAYO® (cemiplimab-rwlc)9

TARPEYO™ (budesonide delayed release capsules)10

TEPMETKO® (tepotinib)11

VTAMA® (tapinarof cream, 1%)12




 

Asembia 2024 recap – Charting the Biosimilars Beat Drop

At AXS’24, Tasmina Hydery, PharmD, MBA, BCGP moderated a session on updates in the biosimilars landscape, coverage, and adoption in the US with Lakesha Farmer, PharmD, MBA (Senior Director, ION Oncology Practice Network, Cencora) and Cate Lockhart, MS, PharmD, PhD (Chief Science Officer, AMCP and Executive Director, Biologics and Biosimilars Collective Intelligence Consortium).
payers

 

Check out the insights and perspectives from their presentation recently uploaded in the FormularyDecisions Biosimilar Hub under Reports & Resources at: Charting the Biosimilars Beat Drop.

Read about the highlights from their presentation in Biosimilars Gaining a Foothold published in Specialty Pharmacy Continuum®.

 

 

 

Upcoming webinar(s)

Academy of Managed Care Pharmacy (AMCP) Webinar hosted by FormularyDecisions

Session: Bracing for the Impact of Biosimilars: Navigating Terrain in the U.S. Market Landscape

Date: June 11, 2024
Time: 2-3 PM ET

Join this interactive, engaging, and informative discussion to discover the keys to thriving in the dynamic biosimilars landscape. In this session, you will gain practical insights on navigating regulatory challenges, seizing opportunities for collaboration, and communicating effectively with stakeholders. Stay ahead of the curve with up-to-date industry trends and expert strategies tailored to driving success in the U.S. biosimilars market.

Learning objectives:

  • Review the U.S. biosimilars market landscape and the current legislative and regulatory environment.
  • Identify key factors affecting payer uptake and provider adoption of biosimilars in the U.S.
  • Explore challenges and opportunities associated with biosimilars for stakeholders across the healthcare continuum.
  • Position yourself for success by leveraging expert strategies and insights to proactively address potential market challenges.


Click below for webinar details and to register through the AMCP website.

FormularyDecisions-body1-504x504

 

Share with your peers

Know someone who could benefit from access to information on over 3,000 pipeline and FDA-approved products? Take a few seconds and use our email template to inform your peers or colleagues about FormularyDecisions.
Man working on a laptop computer

Learn something new

Equip your clinical team with a resource that streamlines the search for relevant product information. Schedule a demo and ensure your team is leveraging all that FormularyDecisions has to offer.

 

Questions?

We welcome your questions and feedback! Please reach out to the FormularyDecisions team today.
 
References:
1. Ye Y, Murdock DJ, Chen C, Liedtke W, Knox CA. Epidemiology of myasthenia gravis in the United States. Front Neurol. 2024 Feb 16;15:1339167.
2. Rodrigues E, Umeh E, Aishwarya, Navaratnarajah N, Cole A, Moy K. Incidence and prevalence of myasthenia gravis in the United States: A claims-based analysis. Muscle Nerve. 2024 Feb;69(2):166-171. 
3. Filsuvez prescribing information. Chiesi USA, Inc.; 2024. https://resources.chiesiusa.com/Filsuvez/FILSUVEZ_PI.pdf 
4. Acthar Gel prescribing information. Mallinckrodt Pharmaceuticals; 2024. https://www.actharhcp.com/globalassets/pdf/acthar_pi.pdf 
5. Asceniv prescribing information. ADMA Biologics, Inc.; 2019. https://www.fda.gov/media/122525/download
6. Elevidys prescribing information. Sarepta Therapeutics; 2023. https://www.elevidyshcp.com/pi 
7. Elfabrio prescribing information. Chiesi USA, Inc.; 2023. https://resources.chiesiusa.com/Elfabrio/ELFABRIO_PI.pdf
8. Enhertu prescribing information. Daiichi Sankyo, Inc.; 2024. https://www.formularydecisions.com/d1-package-inserts/7879?From=ProductCarousel 
9. Libtayo prescribing information. Regeneron Pharmaceuticals, Inc.; 2024. https://www.regeneron.com/downloads/libtayo_fpi.pdf 
10. Tarpeyo prescribing information. Calliditas Therapeutics AB; 2023. https://www.tarpeyo.com/prescribinginformation.pdf 
11. Tepmetko prescribing information. EMD Serono, Inc.; 2024. https://www.emdserono.com/us-en/pi/tepmetko-pi.pdf 
12. Vtama prescribing information. Dermavant Sciences, Inc. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf 
 

a The products listed are in the clinical evaluation stage and have not been approved for use by the FDA. The safety and efficacy of these products have not been established. FormularyDecisions is providing this information to alert you to the status of this product and is not promoting this product generally or otherwise recommending this product for use in the treatment of any disease or inclusion on any formulary for which it has not yet been approved.

b The material is being shared to inform you of the availability of information on FormularyDecisions. In providing this information, FormularyDecisions is not promoting any products mentioned, making claims about risks or benefits, or otherwise recommending any product in general or for any patient or formulary. For complete information about the indications, risks, and benefits of any product, please consult appropriate clinical and safety information, including the complete product label and important safety information. All prescribing decisions and/or coverage decisions should be made independently by individuals with appropriate experience in reliance on their independent judgement.
 
FormularyDecisions is owned and operated by Xcenda L.L.C., which is a subsidiary of Cencora.  
 
The contents of this communication are non-promotional and intended exclusively for healthcare decision makers, formulary committees, and other similar entities responsible for selecting healthcare products for coverage or reimbursement. FormularyDecisions strongly encourages our members to review all available information about a particular product, including but not limited to the product label, and to rely on their experience and expertise in making decisions about coverage or prescribing.